Zovighian Bernard J

SEC source: 0001225208-25-004799 · doc4.xml · derivative · entry 10

Zovighian Bernard J · CIK 0001665141 · Director · CEO

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 7,462 shares

Expires 2025-05-16

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F3 · derivative.exercise_date: These options were granted on May 17, 2018 under the Edwards Lifesciences Corporation Long-Term Stock Incentive Compensation Program and are scheduled to become vested and exercisable commencing one yearafter the grant date in four equal annual installments.

SEC source: 0001225208-25-004799 · doc4.xml · nonDerivative · entry 7

Zovighian Bernard J · CIK 0001665141 · Director · CEO

10b5-1 filing: Plan reported

Ownership: Indirect · By Trust

Disclosed balance after: 11,918

SEC source: 0001225208-25-004799 · doc4.xml · nonDerivative · entry 5

Zovighian Bernard J · CIK 0001665141 · Director · CEO

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 58,283.5511

F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on December 6, 2024.

F2 · price: This transaction was executed in multiple trades at prices ranging from $74.67 to $75.15 The price reported above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide, upon request by the SEC staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares and prices at which the transaction was effected.

SEC source: 0001225208-25-004799 · doc4.xml · nonDerivative · entry 4

Zovighian Bernard J · CIK 0001665141 · Director · CEO

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 64,263.5511

SEC source: 0001225208-25-004799 · doc4.xml · nonDerivative · entry 3

Zovighian Bernard J · CIK 0001665141 · Director · CEO

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 65,745.5511

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on December 6, 2024.

SEC source: 0001225208-25-004799 · doc4.xml · nonDerivative · entry 2

Zovighian Bernard J · CIK 0001665141 · Director · CEO

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 58,283.5511

SEC source: 0001225208-25-004799 · doc4.xml · nonDerivative · entry 1

Zovighian Bernard J · CIK 0001665141 · Director · CEO

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 58,826.5511

SEC source: 0001225208-25-003195 · doc4.xml · derivative · entry 6

Zovighian Bernard J · CIK 0001665141 · Director · CEO

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 7,462

Underlying: Common Stock · 7,463 shares

Expires 2025-05-16

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F4 · derivative.exercise_date: These options were granted on May 17, 2018 under the Edwards Lifesciences Corporation Long-Term Stock Incentive Compensation Program and are scheduled to become vested and exercisable commencing one yearafter the grant date in four equal annual installments.

SEC source: 0001225208-25-003195 · doc4.xml · nonDerivative · entry 4

Zovighian Bernard J · CIK 0001665141 · Director · CEO

10b5-1 filing: Plan reported

Ownership: Indirect · By Trust

Disclosed balance after: 10,436

SEC source: 0001225208-25-003195 · doc4.xml · nonDerivative · entry 3

Zovighian Bernard J · CIK 0001665141 · Director · CEO

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 59,082.9006

F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on December 6, 2024.

F2 · price: This transaction was executed in multiple trades at prices ranging from $69.41 to $69.64 The price reported above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide, upon request by the SEC staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares and prices at which the transaction was effected.

SEC source: 0001225208-25-003195 · doc4.xml · nonDerivative · entry 2

Zovighian Bernard J · CIK 0001665141 · Director · CEO

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 65,246.9006

SEC source: 0001225208-25-003195 · doc4.xml · nonDerivative · entry 1

Zovighian Bernard J · CIK 0001665141 · Director · CEO

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 66,545.9006

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on December 6, 2024.

SEC source: 0001225208-24-006448 · doc4.xml · nonDerivative · entry 1

Zovighian Bernard J · CIK 0001665141 · Director · CEO

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 68,217.9005

F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on February 29, 2024.

SEC source: 0001225208-24-005979 · doc4.xml · nonDerivative · entry 1

Zovighian Bernard J · CIK 0001665141 · Director · CEO

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 76,834.9005

SEC source: 0001225208-24-005886 · doc4.xml · derivative · entry 5

Zovighian Bernard J · CIK 0001665141 · Director · CEO

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 33,500

Underlying: Common Stock · 33,500 shares

Expires not disclosed

F3 · derivative.exercise_price: Reflects the target number of shares (the Target Award) covered by restricted stock unites granted on May 7, 2024 under the Edwards Lifesciences Corporation Long-Term Stock Incentive Compensation Program and are scheduled to vest on May 7, 2027. The number of restricted stock units that vest will depend upon achievement of certain performance goals over a three-year performance period and will range from 0% to 175% of the Target Awards.

F3 · derivative.expiration_date: Reflects the target number of shares (the Target Award) covered by restricted stock unites granted on May 7, 2024 under the Edwards Lifesciences Corporation Long-Term Stock Incentive Compensation Program and are scheduled to vest on May 7, 2027. The number of restricted stock units that vest will depend upon achievement of certain performance goals over a three-year performance period and will range from 0% to 175% of the Target Awards.

SEC source: 0001225208-24-005886 · doc4.xml · derivative · entry 4

Zovighian Bernard J · CIK 0001665141 · Director · CEO

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 178,400

Underlying: Common Stock · 178,400 shares

Expires 2031-05-06

F2 · derivative.exercise_date: These options were granted on May 7, 2024 under the Edwards Lifesciences Corporation Long-Term Stock Incentive Compensation Program and are scheduled to become vested and exercisable commencing one year after the grant date in four equal annual installments.

SEC source: 0001225208-24-005886 · doc4.xml · nonDerivative · entry 2

Zovighian Bernard J · CIK 0001665141 · Director · CEO

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 79,688.9005

SEC source: 0001225208-24-005886 · doc4.xml · nonDerivative · entry 1

Zovighian Bernard J · CIK 0001665141 · Director · CEO

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 80,335.9005

F1 · shares: These restricted stock units were granted on May 7, 2024 under the Edwards Lifesciences Corporation Long-Term Stock Incentive Compensation Program and are scheduled to become vested and exercisable commencing one year after the grant date in four equal annual installments.

SEC source: 0001225208-24-005743 · doc4.xml · nonDerivative · entry 4

Zovighian Bernard J · CIK 0001665141 · Director · CEO

10b5-1 filing: No plan indicated

Ownership: Indirect · 401(k)

Disclosed balance after: 3,267.6552

F2 · balance_after: Reflects shares represented on the most recent statement of the Issuer's 401(k) Plan Administrator.

SEC source: 0001225208-24-005743 · doc4.xml · derivative · entry 5

Zovighian Bernard J · CIK 0001665141 · Director · CEO

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 6,265 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · derivative.exercise_price: On May 4, 2021, the Reporting Person was granted a target number of shares covered by restricted stock units with performance-based vesting requirements over a three-year performance period. On May 1, 2024, the Compensation and Governance Committee of the Board of Directors determined that 117.11% of the target number of shares would vest as of May 4, 2024, and the actual number of shares vested are reflected on this Form 4.

F1 · derivative.expiration_date: On May 4, 2021, the Reporting Person was granted a target number of shares covered by restricted stock units with performance-based vesting requirements over a three-year performance period. On May 1, 2024, the Compensation and Governance Committee of the Board of Directors determined that 117.11% of the target number of shares would vest as of May 4, 2024, and the actual number of shares vested are reflected on this Form 4.

SEC source: 0001225208-24-005743 · doc4.xml · nonDerivative · entry 3

Zovighian Bernard J · CIK 0001665141 · Director · CEO

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 46,835.9005

SEC source: 0001225208-24-005743 · doc4.xml · nonDerivative · entry 2

Zovighian Bernard J · CIK 0001665141 · Director · CEO

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 50,553.9005

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · shares: On May 4, 2021, the Reporting Person was granted a target number of shares covered by restricted stock units with performance-based vesting requirements over a three-year performance period. On May 1, 2024, the Compensation and Governance Committee of the Board of Directors determined that 117.11% of the target number of shares would vest as of May 4, 2024, and the actual number of shares vested are reflected on this Form 4.

F1 · price: On May 4, 2021, the Reporting Person was granted a target number of shares covered by restricted stock units with performance-based vesting requirements over a three-year performance period. On May 1, 2024, the Compensation and Governance Committee of the Board of Directors determined that 117.11% of the target number of shares would vest as of May 4, 2024, and the actual number of shares vested are reflected on this Form 4.

SEC source: 0001225208-24-005743 · doc4.xml · nonDerivative · entry 1

Zovighian Bernard J · CIK 0001665141 · Director · CEO

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 44,288.9005

SEC source: 0001225208-23-007850 · doc4.xml · nonDerivative · entry 1

Zovighian Bernard J · CIK 0001665141 · Director · CEO

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 47,111.4942

F1 · price: The exact unit price to its last decimal number is $83.538983.

SEC source: 0001225208-23-005916 · doc4.xml · derivative · entry 3

Zovighian Bernard J · CIK 0001665141 · President

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 28,150

Underlying: Common Stock · 28,150 shares

Expires not disclosed

F3 · derivative.exercise_price: Reflects the target number of shares (the Target Award) covered by restricted stock units granted on May 11, 2023 under the Edwards Lifesciences Corporation Long-Term Stock Incentive Compensation Program and scheduled to vest on May 11, 2026. The number of restricted stock units that vest will depend upon achievement of certain performance goals over a three-year performance period and will range from 0% to 175% of the Target Awards.

F3 · derivative.expiration_date: Reflects the target number of shares (the Target Award) covered by restricted stock units granted on May 11, 2023 under the Edwards Lifesciences Corporation Long-Term Stock Incentive Compensation Program and scheduled to vest on May 11, 2026. The number of restricted stock units that vest will depend upon achievement of certain performance goals over a three-year performance period and will range from 0% to 175% of the Target Awards.

SEC source: 0001225208-23-005916 · doc4.xml · derivative · entry 2

Zovighian Bernard J · CIK 0001665141 · President

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 173,700

Underlying: Common Stock · 173,700 shares

Expires 2030-05-10

F2 · derivative.exercise_date: These options were granted on May 11, 2023 under the Edwards Lifesciences Corporation Long-Term Stock Incentive Compensation Program and are scheduled to become vested and exercisable commencing one year after the grant date in four equal annual installments.

SEC source: 0001225208-23-005916 · doc4.xml · nonDerivative · entry 1

Zovighian Bernard J · CIK 0001665141 · President

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 44,552.8735

F1 · shares: These restricted stock units were granted on May 11, 2023 under the Edwards Lifesciences Corporation Long-Term Stock Incentive Compensation Program and are scheduled to become vested and exercisable commencing one year after the grant date in four equal annual installments.

SEC source: 0001225208-23-005622 · doc4.xml · nonDerivative · entry 3

Zovighian Bernard J · CIK 0001665141 · President

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 22,027.8735

SEC source: 0001225208-23-005622 · doc4.xml · derivative · entry 4

Zovighian Bernard J · CIK 0001665141 · President

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 1,372

Underlying: Common Stock · 5,003 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · derivative.exercise_price: On May 7, 2020, the Reporting Person was granted a target number of shares covered by restricted stock units with performance-based vesting requirements over a three-year performance period. On May 1, 2023, the Compensation Committee of the Board of Directors determined that 78.48% of the target number of shares would vest as of May 1, 2023, and the actual number of shares vested are reflected on this Form 4.

F1 · derivative.expiration_date: On May 7, 2020, the Reporting Person was granted a target number of shares covered by restricted stock units with performance-based vesting requirements over a three-year performance period. On May 1, 2023, the Compensation Committee of the Board of Directors determined that 78.48% of the target number of shares would vest as of May 1, 2023, and the actual number of shares vested are reflected on this Form 4.

SEC source: 0001225208-23-005622 · doc4.xml · nonDerivative · entry 2

Zovighian Bernard J · CIK 0001665141 · President

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 23,460.8735

SEC source: 0001225208-23-005622 · doc4.xml · nonDerivative · entry 1

Zovighian Bernard J · CIK 0001665141 · President

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 25,783.8735

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · shares: On May 7, 2020, the Reporting Person was granted a target number of shares covered by restricted stock units with performance-based vesting requirements over a three-year performance period. On May 1, 2023, the Compensation Committee of the Board of Directors determined that 78.48% of the target number of shares would vest as of May 1, 2023, and the actual number of shares vested are reflected on this Form 4.

F1 · price: On May 7, 2020, the Reporting Person was granted a target number of shares covered by restricted stock units with performance-based vesting requirements over a three-year performance period. On May 1, 2023, the Compensation Committee of the Board of Directors determined that 78.48% of the target number of shares would vest as of May 1, 2023, and the actual number of shares vested are reflected on this Form 4.

SEC source: 0001225208-23-005437 · doc4.xml · nonDerivative · entry 2

Zovighian Bernard J · CIK 0001665141 · President

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 20,780.8735

SEC source: 0001225208-23-005437 · doc4.xml · nonDerivative · entry 1

Zovighian Bernard J · CIK 0001665141 · President

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 21,150.8735

SEC source: 0001225208-22-009330 · doc4.xml · nonDerivative · entry 1

Zovighian Bernard J · CIK 0001665141 · CVP, TMTT

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 21,246.9647

F1 · kind: The transaction reported in this Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on December 1, 2021.

SEC source: 0001225208-22-008104 · doc4.xml · nonDerivative · entry 1

Zovighian Bernard J · CIK 0001665141 · CVP, TMTT

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 26,007.7011

F1 · kind: The transaction reported in this Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on December 1, 2021.

SEC source: 0001225208-22-007468 · doc4.xml · nonDerivative · entry 1

Zovighian Bernard J · CIK 0001665141 · CVP, TMTT

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 30,816

F1 · price: This transaction was executed in multiple trades at prices ranging from $100.83 to $100.85. The price reported above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide, upon request by the SEC staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares and prices at which the transaction was effected.

SEC source: 0001225208-22-007372 · doc4.xml · nonDerivative · entry 1

Zovighian Bernard J · CIK 0001665141 · CVP, TMTT

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 39,816

F1 · kind: The transaction reported in this Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on December 1, 2021.

SEC source: 0001225208-22-007140 · doc4.xml · nonDerivative · entry 1

Zovighian Bernard J · CIK 0001665141 · CVP, TMTT

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 44,625

SEC source: 0001225208-22-006819 · doc4.xml · derivative · entry 4

Zovighian Bernard J · CIK 0001665141 · CVP, TMTT

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 12,600 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · derivative.exercise_price: On May 8, 2019, the Reporting Person was granted a target number of shares covered by restricted stock units with performance-based vesting requirements over a three-year performance period. On May 2, 2022, the Compensation Committee of the Board of Directors determined that 175% of the target number of shares would vest as of May 8, 2022, and the actual number of shares vested are reflected on this Form 4.

F1 · derivative.expiration_date: On May 8, 2019, the Reporting Person was granted a target number of shares covered by restricted stock units with performance-based vesting requirements over a three-year performance period. On May 2, 2022, the Compensation Committee of the Board of Directors determined that 175% of the target number of shares would vest as of May 8, 2022, and the actual number of shares vested are reflected on this Form 4.

SEC source: 0001225208-22-006819 · doc4.xml · nonDerivative · entry 3

Zovighian Bernard J · CIK 0001665141 · CVP, TMTT

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 46,336

SEC source: 0001225208-22-006819 · doc4.xml · nonDerivative · entry 2

Zovighian Bernard J · CIK 0001665141 · CVP, TMTT

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 53,173

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · shares: On May 8, 2019, the Reporting Person was granted a target number of shares covered by restricted stock units with performance-based vesting requirements over a three-year performance period. On May 2, 2022, the Compensation Committee of the Board of Directors determined that 175% of the target number of shares would vest as of May 8, 2022, and the actual number of shares vested are reflected on this Form 4.

F1 · price: On May 8, 2019, the Reporting Person was granted a target number of shares covered by restricted stock units with performance-based vesting requirements over a three-year performance period. On May 2, 2022, the Compensation Committee of the Board of Directors determined that 175% of the target number of shares would vest as of May 8, 2022, and the actual number of shares vested are reflected on this Form 4.

SEC source: 0001225208-22-006819 · doc4.xml · nonDerivative · entry 1

Zovighian Bernard J · CIK 0001665141 · CVP, TMTT

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 40,573

SEC source: 0001225208-22-006585 · doc4.xml · nonDerivative · entry 2

Zovighian Bernard J · CIK 0001665141 · CVP, TMTT

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 41,206

SEC source: 0001225208-22-006585 · doc4.xml · derivative · entry 4

Zovighian Bernard J · CIK 0001665141 · CVP, TMTT

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 5,200

Underlying: Common Stock · 5,200 shares

Expires not disclosed

F3 · derivative.exercise_price: Reflects the target number of shares (the Target Award) covered by restricted stock units granted on May 3, 2022 under the Edwards Lifesciences Corporation Long-Term Stock Incentive Compensation Program and scheduled to vest on May 3, 2025. The number of restricted stock units that vest will depend upon achievement of certain performance goals over a three-year performance period and will range from 0% to 175% of the Target Awards.

F3 · derivative.expiration_date: Reflects the target number of shares (the Target Award) covered by restricted stock units granted on May 3, 2022 under the Edwards Lifesciences Corporation Long-Term Stock Incentive Compensation Program and scheduled to vest on May 3, 2025. The number of restricted stock units that vest will depend upon achievement of certain performance goals over a three-year performance period and will range from 0% to 175% of the Target Awards.

SEC source: 0001225208-22-006585 · doc4.xml · derivative · entry 3

Zovighian Bernard J · CIK 0001665141 · CVP, TMTT

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 33,700

Underlying: Common Stock · 33,700 shares

Expires 2029-05-02

F2 · derivative.exercise_date: These options were granted on May 3, 2022 under the Edwards Lifesciences Corporation Long-Term Stock Incentive Compensation Program and are scheduled to become vested and exercisable commencing one year after the grant date in four equal annual installments.

SEC source: 0001225208-22-006585 · doc4.xml · nonDerivative · entry 1

Zovighian Bernard J · CIK 0001665141 · CVP, TMTT

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 41,576

F1 · shares: These restricted stock units were granted on May 3, 2022 under the Edwards Lifesciences Corporation Long-Term Stock Incentive Compensation Program and are scheduled to become vested and exercisable commencing one year after the grant date in four equal annual installments.

SEC source: 0001225208-18-003866 · doc4.xml · nonDerivative · entry 1

Zovighian Bernard J · CIK 0001665141 · CVP, TMTT

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 12,588.775

SEC source: 0001225208-17-017472 · doc4.xml · nonDerivative · entry 1

Zovighian Bernard J · CIK 0001665141 · CVP, Surgical Heart Valves

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 13,134.775

F1 · shares: These restricted stock units were granted on November 16, 2017 under the Edwards Lifesciences Corporation Long-Term Stock Incentive Compensation Program and are scheduled to become 50% vested three years after the grant date and 50% vested four years after the grant date.

F2 · balance_after: This amount includes quarterly acquisition of shares under the Edwards Lifesciences Corporation Employee Stock Purchase Plan as reflected on the most recent report of the plan administrator

SEC source: 0001225208-17-009777 · doc4.xml · derivative · entry 3

Zovighian Bernard J · CIK 0001665141 · CVP, Surgical Heart Valves

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 3,175

Underlying: Common Stock · 3,175 shares

Expires not disclosed

F4 · derivative.exercise_price: Reflects the target number of shares (the Target Award) covered by restricted stock units granted under the Edwards Lifesciences Corporation Long-Term Stock Incentive Compensation Program on May 11, 2017 and scheduled to vest on May 11, 2020. The number of restricted stock units that vest will depend upon achievement of certain performance goals over a three-year performance period and will range from 0% to 175% of the Target Award.

F4 · shares: Reflects the target number of shares (the Target Award) covered by restricted stock units granted under the Edwards Lifesciences Corporation Long-Term Stock Incentive Compensation Program on May 11, 2017 and scheduled to vest on May 11, 2020. The number of restricted stock units that vest will depend upon achievement of certain performance goals over a three-year performance period and will range from 0% to 175% of the Target Award.

F4 · derivative.exercise_date: Reflects the target number of shares (the Target Award) covered by restricted stock units granted under the Edwards Lifesciences Corporation Long-Term Stock Incentive Compensation Program on May 11, 2017 and scheduled to vest on May 11, 2020. The number of restricted stock units that vest will depend upon achievement of certain performance goals over a three-year performance period and will range from 0% to 175% of the Target Award.

F4 · derivative.expiration_date: Reflects the target number of shares (the Target Award) covered by restricted stock units granted under the Edwards Lifesciences Corporation Long-Term Stock Incentive Compensation Program on May 11, 2017 and scheduled to vest on May 11, 2020. The number of restricted stock units that vest will depend upon achievement of certain performance goals over a three-year performance period and will range from 0% to 175% of the Target Award.

F4 · derivative.underlying_shares: Reflects the target number of shares (the Target Award) covered by restricted stock units granted under the Edwards Lifesciences Corporation Long-Term Stock Incentive Compensation Program on May 11, 2017 and scheduled to vest on May 11, 2020. The number of restricted stock units that vest will depend upon achievement of certain performance goals over a three-year performance period and will range from 0% to 175% of the Target Award.

F2 · balance_after: This Form 4 reflects changes in beneficial ownership only; it does not identify other securities of the Issuer beneficially owned by the Reporting Person.

SEC source: 0001225208-17-009777 · doc4.xml · derivative · entry 2

Zovighian Bernard J · CIK 0001665141 · CVP, Surgical Heart Valves

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 22,400

Underlying: Common Stock · 22,400 shares

Expires 2024-05-10

F3 · derivative.exercise_date: These options were granted on May 11, 2017 under the Edwards Lifesciences Corporation Long-Term Stock Incentive Compensation Program and are scheduled to become vested and exercisable commencing one year after the grant date in four equal annual installments.

F2 · balance_after: This Form 4 reflects changes in beneficial ownership only; it does not identify other securities of the Issuer beneficially owned by the Reporting Person.